Study of HRS-6093 for advanced solid tumors with KRAS G12D mutation
Part of Cancer clinical trials.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your tumor must have a KRAS G12D mutation, confirmed by a previous test or a central lab.
- You must have tried standard treatment, or be unable to tolerate it, or not have received it yet.
- You need to be in fairly good physical condition (ECOG score 0 or 1).
- You must have at least one measurable tumor and be willing to provide a tumor tissue sample.
- Your organs must be working well enough, and you cannot have serious health issues like untreated brain metastases, active infections, or recent blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This trial tests an experimental drug called LT-010391 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The drug is designed to target this mutation, and the study aims to see if it can help when standard treatments are no longer working.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial tests a new drug called HS-10541, which may target a specific genetic change in your tumor (KRAS G12C mutation). The study aims to see if this drug is safe and effective, either alone or with other cancer treatments, for people with advanced cancer that hasn't responded to standard therapy.
Hear when a new Advanced KRAS G12D Mutant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.